| 1. |
- Bruzzi, M, et al.
(författare)
-
Radiation-hard semiconductor detectors for SuperLHC
- 2005
-
Ingår i: Nuclear Instruments & Methods in Physics Research. Section A: Accelerators, Spectrometers, Detectors, and Associated Equipment. - : Elsevier BV. - 0167-5087 .- 0168-9002. ; 541:1-2, s. 189-201
-
Tidskriftsartikel (refereegranskat)abstract
- An option of increasing the luminosity of the Large Hadron Collider (LHC) at CERN to 1035 cm-2 s-1 has been envisaged to extend the physics reach of the machine. An efficient tracking down to a few centimetres from the interaction point will be required to exploit the physics potential of the upgraded LHC. As a consequence, the semiconductor detectors close to the interaction region will receive severe doses of fast hadron irradiation and the inner tracker detectors will need to survive fast hadron fluences of up to above 1016cm-2. The CERN-RD50 project "Development of Radiation Hard Semiconductor Devices for Very High Luminosity Colliders" has been established in 2002 to explore detector materials and technologies that will allow to operate devices up to, or beyond, this limit. The strategies followed by RD50 to enhance the radiation tolerance include the development of new or defect engineered detector materials (SiC, GaN, Czochralski and epitaxial silicon, oxygen enriched Float Zone silicon), the improvement of present detector designs and the understanding of the microscopic defects causing the degradation of the irradiated detectors. The latest advancements within the RD50 collaboration on radiation hard semiconductor detectors will be reviewed and discussed in this work.
|
|
| 2. |
|
|
| 3. |
- Schneider, A, et al.
(författare)
-
Prevalence and Incidence of Autoimmune Pancreatitis in the Population Living in the Southwest of Germany
- 2017
-
Ingår i: Digestion. - : S. Karger AG. - 1421-9867 .- 0012-2823. ; 96:4, s. 187-198
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background/Aims:</i></b> The prevalence and incidence of autoimmune pancreatitis (AiP) in those living in western countries are largely unknown. We aimed to determine the prevalence of AiP among patients with pancreatitis presenting to our tertiary referral center in Mannheim, Germany; and to estimate the incidence of AiP in the Southwest of Germany. <b><i>Methods:</i></b> We performed a retrospective cross-sectional analysis and determined the prevalence of AiP in patients with acute pancreatitis (AP) or chronic pancreatitis (CP). Patients (<i>n</i> = 704; alcoholic pancreatitis <i>n</i> = 373, nonalcoholic pancreatitis <i>n</i> = 331) were stratified into the Retrospective-Pancreas-Cohort (RPC, period 1998-2008, <i>n</i> = 534) and the Pancreas-Clinic-Cohort (PCC, periods 2008-2010 and 2013-2014, <i>n</i> = 170, with detailed investigation for features of AiP). Diagnosis of AiP was established by International-Consensus-Diagnostic-Criteria and Unifying-Autoimmune-Pancreatitis-Criteria. <b><i>Results:</i></b> In the RPC, the prevalence of AiP was 5.9% (<i>n</i> = 13/221) among individuals with nonalcoholic pancreatitis (<i>n</i> = 1/61 with AP, 1.6%; <i>n</i> = 12/160 with CP, 7.5%). In the PCC, the prevalence of AiP was 9.1% (<i>n</i> = 10/110) among patients with nonalcoholic pancreatitis (<i>n</i> = 2/24 with AP, 8.3%; <i>n</i> = 8/86 with CP, 9.3%), and 1.7% (<i>n</i> = 1/60) among subjects with alcoholic pancreatitis. We estimated the incidence of AiP with 0.29 per 100,000 population each year. <b><i>Conclusion:</i></b> The prevalence rate of AiP may account for 9% of patients with nonalcoholic pancreatitis but is almost never observed in patients with alcoholic pancreatitis. The incidence of AiP in Germany appears lower than 1 per 100,000 population.
|
|
